That's about the best slideshow presentation I've ever seen related to Vascepa. Can Amarin borrow some of these concepts for their own promotional materials?
And this is the first time I've seen it spelled out how teaming up with Pfizer to reach general practitioners is paying off in a big way. KM had suggested that Pfizer might be able to do that in other markets. Like the U.S.???
It's been two years since Pfizer started doing this in Canada and yet Amarin hasn't convinced them to do this elsewhere?
Denner's team is misunderstanding what we mean when we want more communication with shareholders. We don't need to hear that Denner's folks were caught by surprise when KM and the entire board resigned. Not expecting that or planning for it sounds like incompetence on Denner's part and makes some people want to sell their shares. Thus, the daily share price plunge.
What we want to hear in communications is that the company is doing something, anything, to try to show it has new life and is enthusiastically embracing the future with new ideas. Maybe a deal with Pfizer to reach general practitioners in the U.S. and Europe?
Market Data 
Markets 
AI
